AR029437A1 - Tratamiento de la enfermedad neurodegenerativa - Google Patents

Tratamiento de la enfermedad neurodegenerativa

Info

Publication number
AR029437A1
AR029437A1 ARP010100308A ARP010100308A AR029437A1 AR 029437 A1 AR029437 A1 AR 029437A1 AR P010100308 A ARP010100308 A AR P010100308A AR P010100308 A ARP010100308 A AR P010100308A AR 029437 A1 AR029437 A1 AR 029437A1
Authority
AR
Argentina
Prior art keywords
alkyl
cyclin
neurodegenerative diseases
substituted
cycloalkyl
Prior art date
Application number
ARP010100308A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR029437A1 publication Critical patent/AR029437A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a un método de tratamiento de las enfermedades neurodegenerativas en mamíferos mediante la administracion de compuestos que inhiben las enzimas quinasas dependientes de la ciclina. Las enfermedades neurodegenerativas frecuentemente acompanan el proceso de envejecimiento, y estas enfermedades se están haciendo cada vez más frecuentes en todo el mundo cuando la poblacion llega aproximadamente a los 60 anos y más. Se han descubierto compuestos que inhiben ciertas enzimas llamadas quinasas dependientes de la ciclina (cdk) que son utiles para tratar las enfermedades neurodegenerativas. Las quinasas dependientes de la ciclina son enzimas celulares que cumplen funciones esenciales en la regulacion de la division y la proliferacion celular. De los compuestos que inhiben las quinasas dependientes de la ciclina especialmente la cdk5, son utiles en el tratamiento de las enfermedades neurodegenerativas. Un objetivo de esta invencion es proporcionar un método para tratar las enfermedades neurodegenerativas en los mamíferos que comprende administrar una cantidad efectiva de un inhibidor de la cdk. Un método para tratar a un mamífero que sufre una enfermedad neurodegenerativa y que necesita el tratamiento que comprende administrar una cantidad efectiva de un inhibidor de la quinasa dependiente de la ciclina. Dicho método donde dicho inhibidor inhibe la cdk5 más que cualquier otra enzima quinasa dependiente de la ciclina. Dicho método que comprende administrar una cantidad efectiva de un inhibidor de la quinasa dependiente de la ciclina que es un compuesto de la formula (1) o las sales farmacéuticamente aceptables de ellos en donde: La línea de puntos representa una union doble opcional; W es NH, S, SO o SO2; X es O, NH; R1 y R2 se seleccionan independientemente del grupo formado por H, (CH2)n Ar, (CH2)nheteroarilo, (CH2)nheterociclo, alquiloC1-10, cicloalquilo C3-10, alquenilo C2-10, y alquinilo de C2-10, en donde n es 0, 1, 2 o 3 y los grupos (CH2)n Ar, (CH2)n heteroarilo, alquilo, cicloalquilo, alquenilo y alquinilo son optativamente sustituidos por hasta 5 grupos seleccionados de NR4R5, N(O)R4R5, NR4R6Y, fenilo, fenilo sustituido, hidroxi, alcoxi, fenoxi, tiol, tioalquilo, halo, COR4, CO2R4, CONR4R5, SO2NR4R5, SO3R4, PO3R4, aldehído, nitrilo, nitro, heteroariloxi, T(CH2)mQR4, NHC(O)T(CH2)mQR4, O t(CH2)mCO2R4 en donde m es 1-6, T es O, S, NR4, N(O)R4, NR4R6Y, o CR4R5 y Q es O, S, NR5, N(O)R5, o NR5R6Y; R3 es H o alquilo; R4 y r5 se seleccionan independientemente del grupo formado por hidrogeno, alquilo, de C1-6, alquilo sustituido, alquenilo de C2-6, alquinilo de C2-6, (CH2)n Ar, cicloalquilo C3-10, heterociclilo, y heteroarilo, o R4 y R5 junto con el nitrogeno al cual están unidos optativamente forman un anillo que tiene de 3 a 7 átomos de carbono y dicho anillo optativamente contiene 1,2, o 3 heteroátomos seleccionados del grupo formado por nitrogeno, nitrogeno sustituido, oxígeno, azufre; R6 es alquilo; R8 y R9 son independientemente H, alquilo de C1-3, NR4R5, N(O)R4R5, NR4R5R6Y, hidroxi, alcoxi, tiol, tioalquilo, halo, COR4, CO2R4, CONR4R5, SO2NR4R5, SO3R4, PO3R4, CHO, CN o NO2; e Y es un contra ion de halo. Dicho método donde el compuesto administrado tiene la formula (1) donde W es NH y R8 y R9 son ambos hidrogeno y donde existe una union doble entre C5 y C6 y X es O. Dicho método donde el compuesto administrado tiene la formula donde R1 es fenilo o fenilo sustituido. Dicho método donde el compuesto administrado tiene la formula (1) donde R2 es un alquil, alquilo, sustituido, o cicloalquilo no sustituido o sustituido. Las enfermedades neurodegenerativas que pueden ser tratadas son, especialmente, la enfermedad de Alzheimer, la enfermedad de Huntington y la enfermedad de Parkinson.
ARP010100308A 2000-01-27 2001-01-25 Tratamiento de la enfermedad neurodegenerativa AR029437A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17840000P 2000-01-27 2000-01-27

Publications (1)

Publication Number Publication Date
AR029437A1 true AR029437A1 (es) 2003-06-25

Family

ID=22652409

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100308A AR029437A1 (es) 2000-01-27 2001-01-25 Tratamiento de la enfermedad neurodegenerativa

Country Status (22)

Country Link
US (1) US20040224958A1 (es)
EP (1) EP1255755A1 (es)
JP (1) JP2003523358A (es)
KR (1) KR20020070520A (es)
CN (1) CN1433417A (es)
AR (1) AR029437A1 (es)
AU (1) AU1808601A (es)
BR (1) BR0017075A (es)
CA (1) CA2394525A1 (es)
CO (1) CO5280216A1 (es)
CZ (1) CZ20022521A3 (es)
GT (1) GT200100005A (es)
HN (1) HN2001000012A (es)
HU (1) HUP0203803A3 (es)
IL (1) IL150742A0 (es)
PA (1) PA8510801A1 (es)
PE (1) PE20011228A1 (es)
PL (1) PL357634A1 (es)
SK (1) SK10772002A3 (es)
SV (1) SV2002000287A (es)
TN (1) TNSN01018A1 (es)
WO (1) WO2001055148A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
WO2002068419A1 (fr) * 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
DE60216747T2 (de) 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
WO2003032994A2 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
DK1470124T3 (da) * 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
AU2003225072A1 (en) * 2002-04-19 2003-11-03 Smithkline Beecham Corporation Novel compounds
WO2004043367A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
NZ539823A (en) * 2002-11-28 2008-04-30 Schering Aktiengessellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
MXPA05011710A (es) 2003-05-05 2006-01-23 Hoffmann La Roche Derivados de pirimidina con actividad de crf.
PL1685131T3 (pl) 2003-11-13 2007-08-31 Hoffmann La Roche Hydroksyalkilo-podstawione pirydo-7-pirymidyn-7-ony
JP4989233B2 (ja) * 2004-02-14 2012-08-01 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
WO2005082903A1 (en) * 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2006021547A1 (de) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
CA2590294A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US7423042B2 (en) * 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
SG160438A1 (en) * 2005-03-25 2010-04-29 Glaxo Group Ltd Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5- d]pyrimidin-2(1h)-one derivatives
TW200724142A (en) * 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
US8247408B2 (en) 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
WO2007044813A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
AP2710A (en) 2006-09-15 2013-07-30 Pfizer Prod Inc Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors
JP5302389B2 (ja) * 2008-04-29 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー Ｊｎｋのピリミジニルピリドンインヒビター
US8101622B2 (en) 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
EP2344502A2 (en) 2008-10-22 2011-07-20 F. Hoffmann-La Roche AG Pyrimidinyl pyridone inhibitors of jnk
US20130059824A1 (en) * 2009-11-23 2013-03-07 Afraxis, Inc. Methods for treating mild cognitive impairment
CA2784749C (en) 2009-12-18 2017-12-12 E. Premkumar Reddy Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
WO2011156640A2 (en) * 2010-06-09 2011-12-15 Afraxis, Inc. 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
US8912203B2 (en) 2010-06-09 2014-12-16 Afraxis Holdings, Inc. 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
US20130252967A1 (en) * 2010-06-10 2013-09-26 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156775A2 (en) * 2010-06-10 2011-12-15 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156786A2 (en) * 2010-06-10 2011-12-15 Afraxis, Inc. 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
ES2525866T3 (es) * 2010-08-05 2014-12-30 Temple University - Of The Commonwealth System Of Higher Education 8-alquil-7-oxo-7,8-dihidropirido [2,3-d]pirimidina-6-carbonitrilos sustituidos en 2 y usos de los mismos
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
IN2014MN02082A (es) * 2012-03-22 2015-08-21 Genosco
CN106008511B (zh) * 2012-05-14 2018-08-14 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014151682A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
KR20160035411A (ko) * 2014-09-23 2016-03-31 주식회사 오스코텍 LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN108699055B (zh) * 2015-12-13 2020-10-23 杭州英创医药科技有限公司 用作抗癌药物的杂环化合物
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
DK3497103T3 (da) * 2016-08-15 2021-06-14 Pfizer Pyridopyrimdinon-cdk2/4/6-inhibitorer
JP6545747B2 (ja) * 2017-05-09 2019-07-17 山田化学工業株式会社 色素化合物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EA036060B1 (ru) * 2017-07-17 2020-09-21 Пфайзер Инк. Пиридопиримидиноновые ингибиторы cdk2/4/6
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
JP2021523118A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の塩
ES2929406T3 (es) * 2018-05-21 2022-11-29 Nerviano Medical Sciences Srl Compuestos de piridonas heterocondensadas y su uso como inhibidores de IDH
WO2020006210A1 (en) * 2018-06-27 2020-01-02 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
CA3137869A1 (en) * 2019-05-16 2020-11-19 Gregory Cuny Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3157681A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4118082A4 (en) * 2020-03-13 2024-05-01 Prosenestar Llc PYRIDO[2,3-D PYRIMIDIN-7(8H)-ONE AS CDK INHIBITORS
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
KR20000070751A (ko) * 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘

Also Published As

Publication number Publication date
AU1808601A (en) 2001-08-07
HUP0203803A2 (hu) 2003-02-28
CA2394525A1 (en) 2001-08-02
GT200100005A (es) 2002-02-05
WO2001055148A1 (en) 2001-08-02
KR20020070520A (ko) 2002-09-09
US20040224958A1 (en) 2004-11-11
IL150742A0 (en) 2003-02-12
SV2002000287A (es) 2002-01-08
PE20011228A1 (es) 2002-01-18
SK10772002A3 (sk) 2004-01-08
PA8510801A1 (es) 2002-12-11
PL357634A1 (en) 2004-07-26
CN1433417A (zh) 2003-07-30
JP2003523358A (ja) 2003-08-05
BR0017075A (pt) 2002-11-05
EP1255755A1 (en) 2002-11-13
CO5280216A1 (es) 2003-05-30
HUP0203803A3 (en) 2004-09-28
CZ20022521A3 (cs) 2003-02-12
TNSN01018A1 (en) 2005-11-10
HN2001000012A (es) 2001-07-09

Similar Documents

Publication Publication Date Title
AR029437A1 (es) Tratamiento de la enfermedad neurodegenerativa
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
EA200800413A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
TW200639159A (en) Treatment of pain
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
AR060089A1 (es) Tratamiento del dolor
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE284860T1 (de) Neue verwendung von phenylheteroalkylamin- derivaten
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
AR063869A1 (es) Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
EA200970435A1 (ru) Лечение общих расстройств развития
NO20075113L (no) Proteinkinaseinhibitorer
RU2007118727A (ru) Ингибиторы mif
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
DE602005016993D1 (de) Benzothiazolium Verbindungen zur Verwendung in Methoden zur Hemmung der NO Produktion und von TNF alpha und zur Behandlung von Coronavirus Infektionen

Legal Events

Date Code Title Description
FB Suspension of granting procedure